Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
Open Access
- 31 December 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (1) , 106-110
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignanciesNeuro-Oncology, 2022
- Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALLCancer Immunology, Immunotherapy, 2021
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and managementBlood Reviews, 2019
- Early and late hematologic toxicity following CD19 CAR-T cellsBone Marrow Transplantation, 2019
- Toxicities of CD19 CAR‐T cell immunotherapyAmerican Journal of Hematology, 2019
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell TherapiesCNS Drugs, 2018
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapyNature Reviews Clinical Oncology, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Geography and the burden of care in pediatric cancersPediatric Blood & Cancer, 2014